New drug MP0533 takes aim at Hard-to-Treat leukemia

NCT ID NCT05673057

Ongoing Disease control Sponsor: Molecular Partners AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will first find the safest dose and then check if the drug can shrink the cancer. About 249 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MP0533 (a drug that helps immune cells attack leukemia cells)
What this could lead to: If this works, it could offer a new treatment option for people with hard-to-treat AML or MDS.
What could go wrong: This is an early (phase 1/2a) trial, so the drug may not work or could have serious side effects. It is only tested in a small number of people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute disease acute myeloid leukemia leukemia myelodysplastic syndrome myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LEUKEMIA MYELOID NEWLY DIAGNOSED

Contacts and locations

Locations

AP-HP Hôpital Saint-Louis

Paris, 75010, France
Amsterdam UMC - Locatie VUmc

Amsterdam, Netherlands
CHU Bordeaux

Bordeaux, France
Erasmus MC

Rotterdam, Netherlands
Groningen UMC

Groningen, Provincie Groningen, Netherlands
IUCT Oncopole

Toulouse, France
Inselspital, Universitaetsspital Bern

Bern, Canton of Bern, 3010, Switzerland
Universitaetsspital Zuerich

Zurich, Canton of Zurich, 8006, Switzerland
Vilnius University Hospital Santaros Klinikos

Vilnius, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.